Pathology Lab Hadassah Medical Center
Jerusalem, 91120, Israel
Completed
NCT Number: NCT01791322
NovellusDx Tissue Collection Protocol
NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–85 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients that have been diagnosed positive for colon cancer.
- available treatment follow up during cancer treatment
Exclusion criteria
- None
Treatment and study plan
Primary outcomes
-
Correct identification of tumor mutant genes
Time frame: up to 12 month
Correct identification of tumor mutant genes, in over 85% of the cases
Sponsors and collaborators
Lead sponsor
Fore Biotherapeutics
Industry
Registry information
Official study title
An Observational Study to Assess the Oncogenic Status of Colorectal Cancer Patients That Have Undergone Surgery
Important dates
- Study start
- 2014
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Feb 13, 2013
- Registry last updated
- Mar 29, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.